PEP/NEWS — Peptide intel. Daily.

SEMAGLUTIDE PHASE 3 TRIALS SHOW MEAN BODY WEIGHT REDUCTION OF UP TO 15% OVER 68 WEEKSTIRZEPATIDE PRODUCED UP TO 22.5% WEIGHT LOSS IN SURMOUNT-1 TRIAL — HIGHEST IN CLASS TO DATEBPC-157 HAS APPEARED IN OVER 100 PUBLISHED PRECLINICAL STUDIES ACROSS MULTIPLE TISSUE TYPESEPITALON WAS FIRST SYNTHESIZED BY VLADIMIR KHAVINSON IN THE 1980S AT THE ST. PETERSBURG INSTITUTE OF BIOREGULATIONGHK-CU COPPER PEPTIDE CONCENTRATION IN HUMAN PLASMA DECLINES FROM ~200NG/ML AT AGE 20 TO ~80NG/ML BY AGE 60KISSPEPTIN NEURONS IN THE HYPOTHALAMUS ARE THE MASTER SWITCH FOR THE REPRODUCTIVE HORMONE AXISPT-141 (BREMELANOTIDE) IS THE ONLY FDA-APPROVED PEPTIDE TARGETING SEXUAL DESIRE VIA CENTRAL MELANOCORTIN RECEPTORSRETATRUTIDE PHASE 2 DATA SHOWED UP TO 24.2% WEIGHT LOSS AT 48 WEEKS — TRIPLE AGONIST MECHANISM SEMAGLUTIDE PHASE 3 TRIALS SHOW MEAN BODY WEIGHT REDUCTION OF UP TO 15% OVER 68 WEEKSTIRZEPATIDE PRODUCED UP TO 22.5% WEIGHT LOSS IN SURMOUNT-1 TRIAL — HIGHEST IN CLASS TO DATEBPC-157 HAS APPEARED IN OVER 100 PUBLISHED PRECLINICAL STUDIES ACROSS MULTIPLE TISSUE TYPESEPITALON WAS FIRST SYNTHESIZED BY VLADIMIR KHAVINSON IN THE 1980S AT THE ST. PETERSBURG INSTITUTE OF BIOREGULATIONGHK-CU COPPER PEPTIDE CONCENTRATION IN HUMAN PLASMA DECLINES FROM ~200NG/ML AT AGE 20 TO ~80NG/ML BY AGE 60KISSPEPTIN NEURONS IN THE HYPOTHALAMUS ARE THE MASTER SWITCH FOR THE REPRODUCTIVE HORMONE AXISPT-141 (BREMELANOTIDE) IS THE ONLY FDA-APPROVED PEPTIDE TARGETING SEXUAL DESIRE VIA CENTRAL MELANOCORTIN RECEPTORSRETATRUTIDE PHASE 2 DATA SHOWED UP TO 24.2% WEIGHT LOSS AT 48 WEEKS — TRIPLE AGONIST MECHANISM

Last updated May 12, 2026 — I read this morning's peptide research and picked the items that mattered. Fresh brief tomorrow.

◤ Top story · Peter Attia
PETER ATTIA BREAKS DOWN PEPTIDE SCIENCE: LEGITIMATE THERAPEUTICS OR OVERHYPED COMPOUNDS?...

*Attia separates signal from noise in a field crowded with bold claims and thin data.*

Peter Attia

Featured Briefs

◤ Article · Peptide-anchored

GLP-1/GIP CO-AGONIST PRODRUG HITS 7% WEIGHT LOSS IN PHASE 1 BLINDED COHORT...

MBX Biosciences reported preliminary Phase 1 data for MBX 4291, a GLP-1/GIP co-agonist prodrug (a metabolic peptide designed to stay inactive until converted in the body). Mean weight loss hit 7% in a small blinded cohort — with one participant losing 16%. Early data, but the prodrug approach aims to smooth out the side-effect curve seen with semaglutide.

Longevity Technology
▶ Video

MY CURRENT LONGEVITY STACK

Elad Gil is CEO of Gil & Co, a multi-stage investment firm, holding company, and operating company working on the world’s most advanced technologies. Elad is a serial entrepreneur, operating executive, and investor or advisor to private com

Tim Ferriss
▶ Video

WHY LESS FREQUENT TRT INJECTIONS JUST WORK

💥🚀 Hire me to resolve Libido/EQ/Sensation issues on TRT, HRT, or from the use of 5-AR inhibitors. 💥🚀 📞 🧨💣 Book 1 on 1 coaching with Ryan, and solve Libido/EQ problems on TRT, or from hair loss compounds: https://livecortex.com/trt-s

Cortex Labs
▶ Video · Peptide-anchored

WHY THEYR'E WRONG ABOUT BPC-157 BEING DANGEROUS - DR TREVOR BACHMEYER

BPC-157: The Research, the Censorship, and Why Big Pharma Can’t Compete In this episode I deliver a direct rebuttal to claims made on recent podcasts proving that BPC-157 is safe, highly effective, and being suppressed because it can’t be

Dr Trevor Bachmeyer

More Headlines